Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User asks about Redensyl's effectiveness, questioning if it's another ineffective remedy.
The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.
User discusses hair regrowth using RU58841, minoxidil, and dutasteride. Many users praise the progress and ask about the treatments' effectiveness and side effects.
The conversation is about using a hair loss treatment combining 5% RU58841 and 5% minoxidil. The user is considering trying this formula after seeing it advertised.
A user started using RU58841 a month ago after using finasteride and minoxidil for nearly three years, hoping for hair regrowth at the temples. Other users suggest vitamin B supplements and microneedling to improve hair thickness, and one mentions the possibility of a hair transplant for the temples.
The conversation is about finding a source to buy RU58841 in Germany, specifically looking for a PG-free option. Users suggest buying powder and mixing it themselves, with one user recommending a specific website.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
The user is using Minoxidil, Finasteride, Nizoral, Nutrafol supplements, and PRP sessions for hair loss treatment. They are concerned about the effectiveness of these treatments and whether they should continue or consider a hair transplant.
A 21-year-old has started a hair loss routine using topical finasteride and minoxidil, Nioxin stage 4 products, and supplements like biotin. They are considering adding oral minoxidil but are advised to wait and see results first.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
The conversation is about hair regrowth progress using topical finasteride 0.1%, minoxidil 10%, ketoconazole shampoo, and weekly microneedling. The user plans to continue the treatment for another year to assess its effectiveness.
PP405 is being discussed for hair regrowth, with mixed opinions on its effectiveness and legitimacy. Some users report early signs of regrowth, while others are skeptical about its authenticity and results.
OP used oral Dutasteride and Minoxidil but saw significant improvement only after adding PRP treatments. PRP sessions every 4 months maintained the results, though it is expensive.
A 41-year-old man experienced significant hair regrowth using topical finasteride (0.025%), minoxidil, microneedling every two weeks, and occasional Nizoral 2% shampoo. He advises against using creatine due to personal experience with increased hair shedding.
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
Using RU58841 and topical minoxidil together is fine and does not cancel out the benefits of each. Applying both treatments consecutively is acceptable.
Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.
The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
A user shared their 14-month progress using Pyrilutamide and Minoxidil for hair loss, noting improvement and no side effects with these treatments, unlike their negative experiences with Finasteride and RU58841. They emphasized the importance of consistent application for seeing results.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.
The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
PP405 is humorously suggested as a new hair loss cure with "shocking results." The conversation includes references to Minoxidil, finasteride, and RU58841.
A user recently started using nanoxidil 5% for hair loss, particularly on the hairline, and is seeking feedback or experiences from others. The conversation focuses on the effectiveness of nanoxidil.